These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Relationship between genetic polymorphism of NAT2 and susceptibility to urinary bladder cancer].
    Author: Hao GY, Zhang WD, Chen YH, Zhang DX, Zhang YH.
    Journal: Zhonghua Zhong Liu Za Zhi; 2004 May; 26(5):283-6. PubMed ID: 15312364.
    Abstract:
    OBJECTIVE: To study the relationship between genetic polymorphism of NAT2 and susceptibility to bladder cancer. METHODS: NAT2 genotypes were determined by PCR-RFLP method in 69 patients with bladder transitional cell carcinoma and 88 healthy controls. RESULTS: The frequency of NAT2 slow genotypes was 26.1% (18/69) in patients compared with 14.8% (13/88) in controls (P < 0.05). Bladder cancer risk in patients with NAT2 slow genotypes was 2 fold as high as that in patients with NAT2 rapid genotypes. When NAT2 rapid genotypes/non-smoker were used as reference, bladder cancer risk increased to 5.8-fold (P < 0.05). Among the smokers with PY higher than 10, the patients showed a higher frequency of NAT2 slow genotype than controls (P < 0.05). It was also shown that the patients with slow NAT2 genotypes were more likely to have high grade tumor (P < 0.05) and advanced stage tumor (P < 0.01). CONCLUSION: The results suggest that NAT2 genetic polymorphism is associated with bladder cancer susceptibility. People with NAT2 slow genotype have higher bladder cancer risk.
    [Abstract] [Full Text] [Related] [New Search]